Book Online or Call 1-855-SAUSALITO

Sign In  |  Register  |  About Sausalito  |  Contact Us

Sausalito, CA
September 01, 2020 1:41pm
7-Day Forecast | Traffic

  • Search Hotels in Sausalito

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Dermata Therapeutics Inc (NQ: DRMA )

1.150 UNCHANGED
Streaming Delayed Price Updated: 3:59 PM EST, Nov 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Dermata Therapeutics Inc

< Previous 1 2 3 4 5 6 7 8 9 Next >
Dermata Therapeutics Provides Corporate Update and Reports First Quarter 2022 Financial Results
Dermata completes a $5.0 million private placement financing DMT310 Phase 2 rosacea trial topline results expected in H2 2022 SAN DIEGO, CA / ACCESSWIRE / May 16, 2022 / Dermata Therapeutics, Inc.... 
From Dermata Therapeutics
Via AccessWire
Exposures Product Safety
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Dermata Therapeutics Announces Closing of $5.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules
SAN DIEGO, CA / ACCESSWIRE / April 25, 2022 / Dermata Therapeutics, Inc. ("Dermata," or the "Company") (NASDAQ:DRMA) (NASDAQ:DRMAW), a clinical-stage biotechnology company focusing on the treatment of... 
From Dermata Therapeutics
Via AccessWire
Dermata Therapeutics Announces $5.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules
SAN DIEGO, CA / ACCESSWIRE / April 21, 2022 / Dermata Therapeutics, Inc. ("Dermata," or the "Company") (NASDAQ:DRMA) and (NASDAQ:DRMAW), a clinical-stage biotechnology company focusing on the treatment... 
From Dermata Therapeutics
Via AccessWire
Dermata Therapeutics Provides Corporate Update and Reports Full Year 2021 Financial Results
DMT310 Phase 2 rosacea trial is over two-thirds enrolled with topline results expected in H2 2022 DMT310 Phase 2 psoriasis trial to start H1 2022, with topline results expected in H1 2023 DMT310 Phase... 
From Dermata Therapeutics
Via AccessWire
Dermata Therapeutics to Participate in the 2022 Maxim Group Virtual Growth Conference
SAN DIEGO, CA / ACCESSWIRE / March 24, 2022 / Dermata Therapeutics, Inc. (NASDAQ:DRMA) ("Dermata" or the "Company"), a clinical-stage biotechnology company focusing on the treatment of medical and... 
From Dermata Therapeutics
Via AccessWire
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers Palisade Bio (NASDAQ:PALI) shares rose 34.1% to $1.08 during Tuesday's regular session. Trading volume for this security as of 13:31 EST is 52.4 million, which... 
Via Benzinga
75 Biggest Movers From Yesterday
Gainers NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) shares jumped 299.4% to close at $6.23 on Monday as the company received clearance from the FDA to initiate a pharmacokinetic... 
Via Benzinga
42 Stocks Moving in Monday's Pre-Market Session
Gainers Nine Energy Service, Inc. (NYSE: NINE) rose 96.7% to $3.54 in pre-market trading after climbing around 43% on Friday. Shares of low-priced energy stocks jumped as... 
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers Unicycive Therapeutics (NASDAQ:UNCY 
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
Gainers Biofrontera (NASDAQ:BFRA) stock moved upwards by 11.8% to $3.49 during Friday's pre-market session. The market value of their outstanding shares is at $98.9... 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers NeuroOne Medical Tech (NASDAQ:NMTC) shares moved upwards by 12.3% to $3.0 during Thursday's pre-market session. The company's market cap stands at $48.5... 
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Gainers Dermata Therapeutics (NASDAQ:DRMA) shares moved upwards by 26.6% to $1.35 during Friday's regular session. As of 12:30 EST, Dermata Therapeutics's stock is... 
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
Gainers Dermata Therapeutics (NASDAQ:DRMA) stock rose 29.0% to $1.38 during Friday's pre-market session. The company's market cap stands at $11.4 million. Innoviva... 
Via Benzinga
62 Biggest Movers From Yesterday
Gainers American Rebel Holdings, Inc. (NASDAQ: AREB) shares jumped 42.8% to close at $3.07 on Thursday following the company's recent uplisting to the Nasdaq.... 
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers Avenue Therapeutics (NASDAQ:ATXI)... 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Gainers Dermata Therapeutics (NASDAQ:DRMA) shares moved upwards by 26.1% to $1.35 during Thursday's regular session. The current volume of 17.5 million shares is 7266.... 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers Dermata Therapeutics (NASDAQ:DRMA) stock moved upwards by 27.1% to $1.36 during Thursday's pre-market session. The company's market cap stands at $11.3... 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
Good morning, trader! Rub that sleep out our your eyes because we're going over the biggest pre-market stock movers for Thursday! 
Via InvestorPlace
60 Biggest Movers From Yesterday
Gainers US Ecology, Inc. (NASDAQ: ECOL) shares surged 67.7% to close at $47.25 on Wednesday after Republic Services reported it will buy the company at $48 per share in cash.... 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Gainers Doximity (NYSE:DOCS) shares increased by 23.7% to $61.61 during Wednesday's regular session. Doximity's stock is trading at a volume of 8.5 million shares... 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers Nuwellis (NASDAQ:NUWE) stock moved upwards by 13.6% to $1.25 during Wednesday's pre-market session. The market value of their outstanding shares is at $13.1... 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers Sundial Growers (NASDAQ:SNDL) sto... 
Via Benzinga
Mid-Afternoon Market Update: Dow Surges Over 150 Points; Tyson Foods Beats Views
US stocks traded higher later during the session, with the Dow Jones index adding more than 150 points on Monday. 
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Gainers Nuvectis Pharma (NASDAQ:NVCT) stock moved upwards by 132.3% to $7.55 during Monday's regular session. The current volume of 17.0 million shares is 2307.5% of... 
Via Benzinga
Stocks That Hit 52-Week Lows On Tuesday
Tuesday's session saw 109 companies set new 52-week lows. Interesting Points From Today's 52-Week Highs And Lows: The largest company in terms of market cap... 
Via Benzinga
47 Biggest Movers From Yesterday
Gainers Nuvectis Pharma, Inc. (NASDAQ: NVCT) shares surged 144.6% to close at $7.95 on Monday. The company, on Friday, priced its IPO at $5 per share. Anghami Inc. (NASDAQ: ANGH... 
Via Benzinga
32 Stocks Moving In Monday's Mid-Day Session
Gainers Nuvectis Pharma, Inc. (NASDAQ: NVCT) jumped 191.2% to $9.47. The company, on Friday, priced its IPO at $5 per share. Anghami Inc. (NASDAQ: ANGH) shares jumped 51% to $18.... 
Via Benzinga
Mid-Day Market Update: US Stocks Down; Nasdaq Falls 50 Points
Midway through trading Monday, the Dow traded down 0.10% to 35,053.40 while the NASDAQ fell 0.36% to 14,046.74. The S&P also fell, dropping, 0.26% to 4,488.93. Also check out this: Executives Sell Over... 
Via Benzinga
Dermata Therapeutics Shares Plunge 20% Premarket: What Investors Need To Know
Dermata Therapeutics Inc (NASDAQ: DRMA) has requested the FDA to waive the requir 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Photos copyright by Jay Graham Photographer
Copyright © 2010-2020 Sausalito.com & California Media Partners, LLC. All rights reserved.